01 / INDICATION-LEVEL
Indication-level strategy
What is the optimal target population or treatment line to maximize value?
ElevioSight predictive models
Unique forward-looking scenario modeling to inform clinical development and market access strategies.
Book a call
ElevioSight is a unique predictive model designed to simulate the evolution of disease-area drug markets and competitive environments. Our data-driven simulations support strategic decision-making across clinical development, launch planning, and market access. Covering the US and key ex-US markets, our simulations integrate international pricing dynamics, including MFN implications, to help anticipate global value and access trade-offs.
Simulations informing clinical development and market access choices
ElevioSight provides foresight from early clinical development to life-cycle management indications. Our models inform your development and market access strategies with concrete, quantified simulations.
02 / ASSET-LEVEL
Asset-level strategy
How should indications or treatment lines be sequenced for the maximum impact?
03 / PORTFOLIO-LEVEL
Portfolio-level strategy
Which asset choices will best contribute to overall portfolio value?
Models built on robust insights
ElevioSight enables forward-looking outcomes planning by modeling how clinical development decisions will impact pricing, revenue, volume, market share, and ultimately, profitability — leveraging robust disease-area and country-level insights.
- 01
Disease-area expertise
ElevioSight models are regularly updated to reflect the latest changes in global politics, market dynamics, and pricing developments. Our models are tailored to a product's specific attributes — including disease area, indication, and patient population.
- 02
Country-level insights
ElevioSight covers the top 10 global markets, with country-specific simulations. Each simulation is built on value frameworks developed by our market access experts in collaboration with local expert advisors.
- 03
Global pricing and MFN impacts
Anticipate global pricing impacts. ElevioSight models complex cross-country interactions, including MFN schemes such as GENEROUS, GLOBE, and GUARD, enabling teams to anticipate international price referencing risks, evaluate launch scenarios, and make informed decisions that maximize long-term asset value.
USE CASES
How our clients use ElevioSight to maximize the value of their science
ElevioSight models can be leveraged in multiple situations. Here are real-world examples of how our clients use ElevioSight to develop winning strategies across the life-cycle of their assets — maximizing revenues, profits, and patient benefits.
Indication selection in oncology
A large pharmaceutical company used ElevioSight to compare multiple indication options at an early development stage (phase 1) — anticipating how indications and value would evolve across patient sub-populations.
Indication & LCM strategy in immunology
A main pharmaceutical company leverages ElevioSight to assess different life-cycle management options from phase 1 through phase 3 — optimizing the sequencing of indications and selecting the most promising sub-populations.
Competitive readiness
A leading immunology drug — already launched in over 10 indications and expanding into new disease areas — uses ElevioSight to simulate competitive scenarios and forecast how access taken by other companies may impact future revenues.